Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RVX-100
- Development stage
- Phase 2
- Lead developer
- Revogenex
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
RVX-100 is a small molecule drug initially developed by Revogenex Ltd. It has been investigated primarily for the treatment of abdominal pain, diarrhea, and irritable bowel syndrome with diarrhea (IBS-D). The drug was studied in a Phase 2 clinical trial to evaluate its safety and efficacy in treating acute abdominal pain associated with IBS-D. The development status of RVX-100 is currently suspended. Its exact mechanism of action is not clearly defined in available data. It belongs to the class of small molecule therapeutics targeting nervous system diseases and digestive system disorders.
- Other names
- RVX-100RVX100RVX 100
Beyond the preview
Go deeper on RVX-100.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RVX-100.